CLL/MCL Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Advanced Skin Cancers
CLL/MCL
Multiple Myeloma
Non–Small Cell Lung Cancer
Ovarian Cancer
JNCCN
Editor:
Jeremy S. Abramson, MD, MMSc
Advertisement
Advertisement
Resources For Your Patients
JADPRO Roundtable Series: Best Practices in the Use of BTK Inhibitors in CLL
NCCN COVID-19 Resources Page
ASH: COVID-19 Resources for Managing Blood Cancers
ASCO: COVID-19 Medical Resources
Cancer.gov
Patient Power
UpToDate
Leukemia & Lymphoma Society
JNCCN: How To Manage Cancer Care During COVID-19 Pandemic
NCCN Guidelines for Patients for CLL
CLL Society
NCCN Guidelines for Patients
JNCCN Spotlights
?
Acalabrutinib
Zanubrutinib
(Update) Acalabrutinib in CLL and MCL
Update Venetoclax in CLL
View More >
Advertisement
Resources
For your Patients
Copyright ©
2026
National Comprehensive Cancer Network, All Rights Reserved
